Masimo (NASDAQ:MASI) Upgraded at Wall Street Zen

Key Points

• Masimo has been upgraded from a "hold" rating to a "buy" rating by analysts at Wall Street Zen, signaling increased confidence in the stock's performance.
• Analysts have set a consensus rating of "Buy" with an average price target of $194.60 for Masimo's shares, indicating potential growth.
• In the latest quarter, Masimo reported an EPS of $1.33, surpassing estimates, and showing a 7.7% year-over-year revenue increase.

Masimo (NASDAQ:MASI - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Sunday.

Several other research analysts have also commented on MASI. Zacks Research raised Masimo from a "hold" rating to a "strong-buy" rating in a research report on Wednesday, September 3rd. BTIG Research reaffirmed a "buy" rating and set a $198.00 price target on shares of Masimo in a research report on Thursday, September 11th. Finally, Piper Sandler lifted their price target on Masimo from $200.00 to $210.00 and gave the stock an "overweight" rating in a research report on Wednesday, August 6th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of "Buy" and an average price target of $194.60.

Masimo Trading Up 1.2%

Shares of NASDAQ:MASI opened at $141.40 on Friday. Masimo has a 12-month low of $131.01 and a 12-month high of $194.88. The company has a market capitalization of $7.68 billion, a PE ratio of -16.60 and a beta of 1.23. The business has a 50 day moving average of $148.34 and a two-hundred day moving average of $156.72. The company has a current ratio of 2.14, a quick ratio of 1.61 and a debt-to-equity ratio of 0.57.

Masimo (NASDAQ:MASI - Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical equipment provider reported $1.33 EPS for the quarter, topping the consensus estimate of $1.22 by $0.11. The firm had revenue of $370.90 million during the quarter, compared to analysts' expectations of $368.65 million. Masimo had a positive return on equity of 26.54% and a negative net margin of 24.85%.The firm's revenue for the quarter was up 7.7% on a year-over-year basis. During the same period in the previous year, the business earned $0.86 earnings per share. As a group, analysts forecast that Masimo will post 4.1 EPS for the current year.

Insider Activity at Masimo

In related news, Director William R. Jellison bought 3,000 shares of the stock in a transaction dated Monday, August 11th. The stock was acquired at an average price of $145.98 per share, for a total transaction of $437,940.00. Following the completion of the purchase, the director owned 4,790 shares in the company, valued at $699,244.20. This represents a 167.60% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. 9.70% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Masimo

Large investors have recently modified their holdings of the stock. Versant Capital Management Inc raised its holdings in Masimo by 2,542.9% during the first quarter. Versant Capital Management Inc now owns 1,480 shares of the medical equipment provider's stock valued at $247,000 after buying an additional 1,424 shares in the last quarter. GAMMA Investing LLC grew its position in Masimo by 26,284.3% during the first quarter. GAMMA Investing LLC now owns 122,951 shares of the medical equipment provider's stock worth $20,484,000 after buying an additional 122,485 shares in the last quarter. NBC Securities Inc. acquired a new stake in Masimo during the first quarter worth about $61,000. RFG Advisory LLC grew its position in Masimo by 73.6% during the first quarter. RFG Advisory LLC now owns 6,780 shares of the medical equipment provider's stock worth $1,130,000 after buying an additional 2,875 shares in the last quarter. Finally, UMB Bank n.a. grew its position in Masimo by 134.0% during the first quarter. UMB Bank n.a. now owns 447 shares of the medical equipment provider's stock worth $74,000 after buying an additional 256 shares in the last quarter. 85.96% of the stock is owned by institutional investors.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.